You are reading the report for 2026-09-30. The figures are as they stood that day and are not revised. See the current report →

Daily Special Report

Published Oct 1

The Street Split Watch List

Where the analysts disagree

4 companiesData through Sep 30

ZBIO carries the widest gap between target and price at +106%, while KMX has the smallest at +13%. PNFP and MDB share a gap of +25%. These comparisons use the most recent target against the price when it was set; the feed covers published grade changes and price targets, and analyst opinion is not a recommendation.

Gap between the latest price target and the current priceTARGET VS CURRENT PRICE · PUBLISHED RANGEPNFP+25% $63 – $190KMX+13% $53 – $70MDB+25% $385 – $470ZBIO+106%

Entry by entry — why each one is on the board

PNFPPinnacle Financial Partners, Inc.
Split2 up / 1 down
Target vs price+25%
Range$63 – $190

PNFP is the only company here with 2 up / 1 down, while its gap between target and price, +25%, is shared with MDB. Its disclosed band is the only one here at $63 – $190.

split: 2 up, 1 down · targets $63-$190 · Barclays, HSBC, Oppenheimer

KMXCarMax, Inc.
Split—
Target vs price+13%
Range$53 – $70

Among the four, KMX has the smallest gap between target and price at +13%. Its disclosed band, $53 – $70, is the smallest of the 3 here.

targets $53-$70 · Barclays, Morgan Stanley, RBC Capital

MDBMongoDB, Inc.
Split—
Target vs price+25%
Range$385 – $470

By contrast, MDB has no up-or-down split (—), matching KMX and ZBIO. Its disclosed band of $385 – $470 is the biggest of the 3 here.

targets $385-$470 · BMO Capital, D.A. Davidson, Piper Sandler

ZBIOZenas BioPharma, Inc.
Split—
Target vs price+106%
Range—

At ZBIO, the gap between target and price is +106%, the biggest of the 4 here. No disclosed band is shown (—), unlike the other companies.

Guggenheim

How this board was built

Grade changes and price targets published in the latest analyst feed. “Target vs price” compares the most recent target with the price at the time it was set. Analyst opinion is not a recommendation.